The full benefits of adult pneumococcal vaccination: A systematic review
Introduction. Pneumococcal disease causes significant morbidity and mortality in both developing and developed countries, causing 1.6 million deaths annually []—more than seasonal influenza [], malaria [], or HIV/AIDS [].Pneumococcal disease comprises several clinical syndromes caused by the Streptococcus pneumoniae (pneumococcus) bacterium. Case fatality rates vary depending on the ...
The remarkable history of pneumococcal vaccination: an ongoing
The early years of pneumococcal vaccine development. More than one hundred years ago, the South African gold mining industry asked British physician, Almroth Wright, who had previously worked on a vaccine against typhoid fever, to study vaccination against pneumococcal pneumonia in men working in gold mines located on the Witwatersrand [].Whether practical or altruistic, the motivation of the ...
Pneumococcal Vaccines: Past Findings, Present Work, and Future
2. Inclusion of New Polysaccharide Serotypes into PCVs. Licensed PCVs have been extremely important in reducing pneumococcal disease worldwide. These vaccines included 7 to 13 PS from different pneumococcal serotypes conjugated to carrier proteins [].After the introduction of PCV7 in the immunization program of several countries, a high rate of protection of vaccinated children has been ...
The remarkable history of pneumococcal vaccination: an ongoing
Thus began the era of pneumococcal conjugate vaccine (PCV), starting with PCV7, progressing to PCV10 and PCV13, and, most recently, PCV15 and PCV20. However, these vaccines remain serotype specific, posing the challenge of new serotypes replacing vaccine types. Current research addresses serotype-independent vaccines which, so far, has been a ...
Emerging vaccine strategies against the incessant pneumococcal ...
The incidence of invasive pneumococcal disease (IPD) caused by infection with the pathogen Streptococcus pneumoniae (Spn) has been on a downward trend for decades due to worldwide vaccination ...
Pneumococcal vaccination-A literature review and practice ...
Pneumococcal vaccines are available in two formulations, the unconjugated purified polysaccharide (PPSV) and the conjugated formulation (PCV), which leads to a more robust and prolonged immune response. There have been dramatic reductions in mortality attributed to invasive pneumococcal disease over the past 2 decades due to improved ...
Effectiveness of Pneumococcal Vaccination Against Pneumococcal ...
Background: Despite use of the 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) over the last decade, the disease burden of pneumococcal pneumonia is still high. We evaluated the field effectiveness of PCV13, PPSV23, and sequential vaccination against pneumococcal pneumonia in older adults.
Effect and cost-effectiveness of pneumococcal conjugate vaccination: a
Two pneumococcal conjugate vaccines (PCVs), ten-valent PCV (PCV10) and 13-valent PCV (PCV13), are also used in children. These PCVs have been widely adopted in high-income countries and have also been introduced in low-income countries with the support of Gavi, the Vaccine Alliance. However, more than 40 countries have yet to introduce PCVs ...
Effectiveness of pneumococcal vaccines in preventing pneumonia ...
Introduction S. pneumoniae can cause a wide spectrum of diseases, including invasive pneumococcal disease and pneumonia. Two types of pneumococcal vaccines are indicated for use in adults: 23-valent pneumococcal polysaccharide vaccines (PPV23) and a 13-valent pneumococcal conjugate vaccine (PCV13). Objective To systematically review the literature assessing pneumococcal vaccine effectiveness ...
Recent progress in pneumococcal protein vaccines
Abstract. Pneumococcal infections continue to pose a significant global health concern, necessitating the development of effective vaccines. Despite the progress shown by pneumococcal polysaccharide and conjugate vaccines, their limited coverage and the emergence of non-vaccine serotypes have highlighted the need for alternative approaches.
The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine
Essays are opinion pieces on a topic of broad interest to a general medical audience. ... of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial. Vaccine. Elsevier Ltd; 2012;30: 5132-40. pmid:22683519
PDF Emerging vaccine strategies against the incessant pneumococcal ...
In the limited data looking at overall pneumococcal incidence before and after the introduction of the 7- and 13-valent conjugate vaccine, it was found that a small number of non-included ...
Vaccine Confidence, Coverage, and Hesitancy Worldwide: A Literature
Thesis Summary . Vaccines are one of the world's most impactful medical therapies. They are cost-effective, successfully proven, and one of the quickest treatment options available today (Clark ... least 1 dose of varicella vaccine; and 4 or more doses of pneumococcal conjugate vaccine. Compared to the 86% of children worldwide who have ...
Effect of pneumococcal conjugate vaccines and SARS-CoV-2 on
The increase in non-PCV13 serotypes associated with antibiotic resistance is concerning, especially the increase of penicillin resistance linked to serotypes 11A and 24F. The future use of PCVs with an increasingly broad spectrum (such as PCV20, which includes serotype 11A) could reduce the impact of antibiotic resistance for non-PCV13 serotypes. The use of antibiotics to prevent co-infections ...
Recent progress in pneumococcal protein vaccines
Pneumococcal infections continue to pose a significant global health concern, necessitating the development of effective vaccines. Despite the progress shown by pneumococcal polysaccharide and conjugate vaccines, their limited coverage and the emergence of non-vaccine serotypes have highlighted the need for alternative approaches. Protein-based ...
Impact of vaccination on the epidemiology and prognosis of pneumonia
In 1977 a pneumococcal vaccine was licensed that protected against 14 serotypes, in 1983 it was expanded to protect against 23 serotypes. This is a polysaccharide vaccine called PPSV23. It remained in force for more than 20 years since with penicillin and later the appearance of other antibiotics, the morbidity and mortality of this disease ...
PDF Pneumococcal Vaccination in Children with Cancer Te-Yu Hung
advent and availability of highly immunogenic pneumococcal conjugate vaccines (PCVs), there is renewed interest in the evaluation of this in a wider cohort of immunocompromised population. The primary aim of this thesis was to evaluate the immunogenicity and safety of a single dose of 13-valent pneumococcal conjugate vaccine (PCV13) in children on
Frontiers
The development of pneumococcal protein vaccines has been fueled by advancements in understanding the biology and pathogenesis of S. pneumoniae. Identification of key virulence factors and surface proteins involved in host-pathogen interactions has facilitated the selection of potential vaccine candidates ( 19 ).
Frontiers
Streptococcus pneumoniae is an opportunistic pathogen that causes over 1 million deaths annually despite the availability of several multivalent pneumococcal conjugate vaccines (PCVs). Due to the limitations surrounding PCVs along with an evolutionary rise in antibiotic-resistant and unencapsulated strains, conserved immunogenic proteins as vaccine targets continue to be an important field of ...
Pneumococcal whole-cell and protein-based vaccines: Changing the
1. Introduction. Pneumococcal conjugate vaccines (PCVs) provide clear and tangible public health benefits from direct effects on vaccinated persons and indirect effects from herd immunity, produced by elimination of nasopharyngeal (NP) colonization.[] Early on, some experts envisioned that a PCV that included the 7 most common serotypes would have the potential to prevent up to 88% of invasive ...
Pneumococcal Vaccination: Who and When to Vaccinate
The PCV20 dose should be given at least 5 years after the last pneumococcal vaccine. Their vaccines are then complete. The second dose of PPSV23 should be given at least 8 weeks after PCV13 and 5 years after PPSV23. No additional pneumococcal vaccines are recommended until at least age 65 years.
Effectiveness of pneumococcal vaccines in preventing pneumonia in
The influenza vaccine is known to be effective in reduction of any-CAP and hence, combined vaccination with pneumococcal vaccine might overestimate the VE attributed to pneumococcal vaccine in the general population [53, 54]. An inherent limitation of observational studies is that vaccines are channeled to certain populations.
Relationship between immune response to pneumococcal conjugate vaccines
Introduction: Streptococcus pneumoniae is a leading cause of morbidity and mortality worldwide. Widespread infant vaccination with pneumococcal conjugate vaccines (PCVs) substantially reduced vaccine-serotype pneumococcal disease by direct protection of immunized children and indirect protection of the community via decreased nasopharyngeal carriage and transmission.
COMMENTS
Introduction. Pneumococcal disease causes significant morbidity and mortality in both developing and developed countries, causing 1.6 million deaths annually []—more than seasonal influenza [], malaria [], or HIV/AIDS [].Pneumococcal disease comprises several clinical syndromes caused by the Streptococcus pneumoniae (pneumococcus) bacterium. Case fatality rates vary depending on the ...
The early years of pneumococcal vaccine development. More than one hundred years ago, the South African gold mining industry asked British physician, Almroth Wright, who had previously worked on a vaccine against typhoid fever, to study vaccination against pneumococcal pneumonia in men working in gold mines located on the Witwatersrand [].Whether practical or altruistic, the motivation of the ...
2. Inclusion of New Polysaccharide Serotypes into PCVs. Licensed PCVs have been extremely important in reducing pneumococcal disease worldwide. These vaccines included 7 to 13 PS from different pneumococcal serotypes conjugated to carrier proteins [].After the introduction of PCV7 in the immunization program of several countries, a high rate of protection of vaccinated children has been ...
Thus began the era of pneumococcal conjugate vaccine (PCV), starting with PCV7, progressing to PCV10 and PCV13, and, most recently, PCV15 and PCV20. However, these vaccines remain serotype specific, posing the challenge of new serotypes replacing vaccine types. Current research addresses serotype-independent vaccines which, so far, has been a ...
The incidence of invasive pneumococcal disease (IPD) caused by infection with the pathogen Streptococcus pneumoniae (Spn) has been on a downward trend for decades due to worldwide vaccination ...
Pneumococcal vaccines are available in two formulations, the unconjugated purified polysaccharide (PPSV) and the conjugated formulation (PCV), which leads to a more robust and prolonged immune response. There have been dramatic reductions in mortality attributed to invasive pneumococcal disease over the past 2 decades due to improved ...
Background: Despite use of the 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) over the last decade, the disease burden of pneumococcal pneumonia is still high. We evaluated the field effectiveness of PCV13, PPSV23, and sequential vaccination against pneumococcal pneumonia in older adults.
Two pneumococcal conjugate vaccines (PCVs), ten-valent PCV (PCV10) and 13-valent PCV (PCV13), are also used in children. These PCVs have been widely adopted in high-income countries and have also been introduced in low-income countries with the support of Gavi, the Vaccine Alliance. However, more than 40 countries have yet to introduce PCVs ...
Introduction S. pneumoniae can cause a wide spectrum of diseases, including invasive pneumococcal disease and pneumonia. Two types of pneumococcal vaccines are indicated for use in adults: 23-valent pneumococcal polysaccharide vaccines (PPV23) and a 13-valent pneumococcal conjugate vaccine (PCV13). Objective To systematically review the literature assessing pneumococcal vaccine effectiveness ...
Abstract. Pneumococcal infections continue to pose a significant global health concern, necessitating the development of effective vaccines. Despite the progress shown by pneumococcal polysaccharide and conjugate vaccines, their limited coverage and the emergence of non-vaccine serotypes have highlighted the need for alternative approaches.
Essays are opinion pieces on a topic of broad interest to a general medical audience. ... of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial. Vaccine. Elsevier Ltd; 2012;30: 5132-40. pmid:22683519
In the limited data looking at overall pneumococcal incidence before and after the introduction of the 7- and 13-valent conjugate vaccine, it was found that a small number of non-included ...
Thesis Summary . Vaccines are one of the world's most impactful medical therapies. They are cost-effective, successfully proven, and one of the quickest treatment options available today (Clark ... least 1 dose of varicella vaccine; and 4 or more doses of pneumococcal conjugate vaccine. Compared to the 86% of children worldwide who have ...
The increase in non-PCV13 serotypes associated with antibiotic resistance is concerning, especially the increase of penicillin resistance linked to serotypes 11A and 24F. The future use of PCVs with an increasingly broad spectrum (such as PCV20, which includes serotype 11A) could reduce the impact of antibiotic resistance for non-PCV13 serotypes. The use of antibiotics to prevent co-infections ...
Pneumococcal infections continue to pose a significant global health concern, necessitating the development of effective vaccines. Despite the progress shown by pneumococcal polysaccharide and conjugate vaccines, their limited coverage and the emergence of non-vaccine serotypes have highlighted the need for alternative approaches. Protein-based ...
In 1977 a pneumococcal vaccine was licensed that protected against 14 serotypes, in 1983 it was expanded to protect against 23 serotypes. This is a polysaccharide vaccine called PPSV23. It remained in force for more than 20 years since with penicillin and later the appearance of other antibiotics, the morbidity and mortality of this disease ...
advent and availability of highly immunogenic pneumococcal conjugate vaccines (PCVs), there is renewed interest in the evaluation of this in a wider cohort of immunocompromised population. The primary aim of this thesis was to evaluate the immunogenicity and safety of a single dose of 13-valent pneumococcal conjugate vaccine (PCV13) in children on
The development of pneumococcal protein vaccines has been fueled by advancements in understanding the biology and pathogenesis of S. pneumoniae. Identification of key virulence factors and surface proteins involved in host-pathogen interactions has facilitated the selection of potential vaccine candidates ( 19 ).
Streptococcus pneumoniae is an opportunistic pathogen that causes over 1 million deaths annually despite the availability of several multivalent pneumococcal conjugate vaccines (PCVs). Due to the limitations surrounding PCVs along with an evolutionary rise in antibiotic-resistant and unencapsulated strains, conserved immunogenic proteins as vaccine targets continue to be an important field of ...
1. Introduction. Pneumococcal conjugate vaccines (PCVs) provide clear and tangible public health benefits from direct effects on vaccinated persons and indirect effects from herd immunity, produced by elimination of nasopharyngeal (NP) colonization.[] Early on, some experts envisioned that a PCV that included the 7 most common serotypes would have the potential to prevent up to 88% of invasive ...
The PCV20 dose should be given at least 5 years after the last pneumococcal vaccine. Their vaccines are then complete. The second dose of PPSV23 should be given at least 8 weeks after PCV13 and 5 years after PPSV23. No additional pneumococcal vaccines are recommended until at least age 65 years.
The influenza vaccine is known to be effective in reduction of any-CAP and hence, combined vaccination with pneumococcal vaccine might overestimate the VE attributed to pneumococcal vaccine in the general population [53, 54]. An inherent limitation of observational studies is that vaccines are channeled to certain populations.
Introduction: Streptococcus pneumoniae is a leading cause of morbidity and mortality worldwide. Widespread infant vaccination with pneumococcal conjugate vaccines (PCVs) substantially reduced vaccine-serotype pneumococcal disease by direct protection of immunized children and indirect protection of the community via decreased nasopharyngeal carriage and transmission.